← Back to headlines
Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.
TD Cowen has downgraded Novo Nordisk due to concerns over the potential loss of its semaglutide patent and the company's pipeline outlook, despite still seeing a 6% upside for shares.
10 Mar, 09:48 — 10 Mar, 16:09
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (56/100)4 sources30/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left1
Left (1)
cnbc
Center2
Center (2)
forbesmarketwatch
Right1
Right (1)
naftemporiki
Far R
Geographic diversity— 2 regions9/34
US3Greece1
Sources
Showing 3 of 4 sources
cnbcMostly Factual45d ago
TD Cowen downgrades Novo Nordisk on concerns over semaglutide patent loss, pipeline outlook
TD Cowen still sees shares of Novo Nordisk adding 6% from here.
Read full article →marketwatchMostly Factual45d ago
Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.
Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
By Steve Goldstein
Read full article →forbes45d ago
FDA Warns Novo Nordisk Over Potential Unreported Ozempic Side Effects, Deaths - Forbes
FDA Warns Novo Nordisk Over Potential Unreported Ozempic Side Effects, Deaths Forbes
Read full article →Coverage Timeline
First report: marketwatch · 10 Mar, 09:48|Full coverage: 4 · 10h|Window: 10h
Left-leaningCenterRight-leaning
